Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 17, 2019, by Xenetic Biosciences, Inc. (NASDAQ: XBIO). The report details the entry into a material definitive agreement for a public offering and the completion of an asset acquisition on July 19, 2019. The filing also addresses the appointment of a new director and the company's regained compliance with NASDAQ listing rules.
Key Financial Metrics and Capital Events
- Public Offering: The Company sold 1,730,000 shares of Common Stock, 570,000 Pre-Funded Warrants, and 2,300,000 Purchase Warrants at a combined price of $6.50 per unit.
- Gross Proceeds: Approximately $15.0 million from the primary offering.
- Overallotment: The underwriter exercised an option for 160,000 additional Purchase Warrants, generating $1,600 in additional proceeds.
- Net Proceeds: Approximately $13.4 million after deducting underwriting discounts and offering expenses.
- Use of Proceeds: Funds are designated for research and development, clinical programs (specifically the XCART technology), and general corporate purposes.
- Warrant Terms: Purchase Warrants are immediately exercisable at $13.00 per share and expire five years from issuance. They trade under the symbol "XBIOW."
Material Changes and Acquisitions
- XCART Technology Acquisition: On July 19, 2019, the Company completed the acquisition of XCART technology from Hesperix SA and its owners.
- Consideration: The Company issued approximately 406,250 shares of Common Stock to the sellers as consideration.
- Assignment Shares: Approximately 218,750 shares were issued to OPKO Pharmaceuticals, LLC and the Scripps Research Institute pursuant to a prior assignment agreement. These shares were issued under Section 4(a)(2) and Rule 506(b) exemptions.
- NASDAQ Compliance: The offering resulted in the number of publicly held shares exceeding 500,000, allowing the Company to regain compliance with NASDAQ Marketplace Rule 5550(a)(4).
Management Commentary, Governance, and Risks
- Board Appointment: Dr. Alexey Vinogradov was appointed to the Board of Directors effective upon the closing of the Acquisition. He will serve until the 2019 annual meeting of stockholders.
- Unregistered Sales: The Assignment Shares issued to OPKO and the Institute were not registered under the Securities Act of 1933. The Company agreed to file a registration statement for their resale as soon as practicable.
- Warrant Agency: A Warrant Agency Agreement was entered into with Empire Stock Transfer, Inc. to act as the transfer agent for the Purchase Warrants.
Investor Verification Checklist
- Verify the final net proceeds of $13.4 million against the actual cash balance in the subsequent 10-Q or 10-K filing.
- Confirm the trading status and volume of the new Purchase Warrants (XBIOW) on the NASDAQ Capital Market.
- Review the progress of the XCART technology development funded by the offering proceeds.
- Monitor the filing of the registration statement for the resale of the unregistered Assignment Shares issued to OPKO and the Scripps Research Institute.
- Check for any updates regarding the Company's continued compliance with NASDAQ listing standards.